Travere Therapeutics' FILSPARI Endorsed in New KDIGO Guidelines for IgA Nephropathy Treatment

New Guidelines Elevate Treatment Standards for IgA Nephropathy with FILSPARI's Endorsement

Travere Therapeutics, alongside CSL Vifor, endorses the recently updated 2025 clinical practice guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) for managing IgA Nephropathy (IgAN). These guidelines establish essential diagnostic criteria and treatment goals aimed at improving patient care, with a particular focus on achieving remission of proteinuria and slowing the decline of estimated glomerular filtration rate (eGFR). The recommended target for proteinuria is set at less than 0.5 g/day, with an ideal goal of under 0.3 g/day, reflecting a shift towards more stringent management of the condition. This significant update underscores the urgent need for effective treatment strategies to address the complexities of IgAN.

Central to the new guidelines is the inclusion of FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), as a potential first-line treatment for IgAN-induced nephron loss. This recommendation represents a notable departure from the traditional Renin-Angiotensin System inhibitor (RASi)-first approach, positioning FILSPARI as a leading option for clinicians. The drug's efficacy has been demonstrated in the PROTECT trial, which enrolled more patients than all prior RASi trials combined, highlighting its robust performance. As emphasized by Prof. Dr. med. Jürgen Floege from RWTH Aachen University Hospital, these updated guidelines mark a pivotal advancement for the IgAN community, providing clarity and direction for treatment decisions aimed at enhancing long-term kidney health.

Furthermore, Dr. Achim Obergfell, Global Medical Lead at Travere, articulates that the endorsement of FILSPARI in these guidelines reflects its favorable benefit-risk profile. The drug effectively reduces proteinuria and slows down the progression of kidney function loss, while maintaining a good safety profile. This clear recognition of FILSPARI within the updated guidelines signifies a commitment to improving patient outcomes amidst the challenges posed by IgAN. The integration of these new recommendations not only supports clinicians in their treatment approaches but also empowers patients navigating their care.

In addition to the focus on FILSPARI, the updated KDIGO guidelines serve as a vital resource for healthcare professionals, facilitating informed treatment decisions in IgAN management. The emphasis on achieving specific proteinuria targets and eGFR preservation aligns with broader goals of enhancing the overall quality of care for patients suffering from this condition. This collaborative effort between Travere Therapeutics and CSL Vifor demonstrates a unified approach to advancing treatment paradigms within the renal health landscape, ultimately striving for better patient outcomes in IgA Nephropathy management.